Developments in Post-Stroke Spasticity Care with Early Use of Botulinum Toxin A: A Review

Abstract

Spasticity is one of the most common and disabling complications of stroke. Most of these patients notably experience both muscle-based and non-muscle-based pain. This negatively affects their quality of life as well as aggravates caregiver burden. Post-stroke spasticity (PSS) may furthermore lead to several complications related to limited mobility, both motor (eg, contractures) and non-motor (cognitive decline, depression) if left untreated. It is thus crucial to address this with safe and effective means such as botulinum toxin therapy as early as possible. We aim to demonstrate the utility of botulinum toxin (BoNT) in PSS treatment and how early intervention may be preferable to late spasticity control for patients. Literature search and evaluation were done using the traditional evidence hierarchy. Early intervention with botulinum toxin A (BoNTA) demonstrated a more marked reduction in both spasticity and spasticity-related pain with longer required intervals to reinjection.

 

Keywords: Botulinum Toxin, Early Use/Intervention, Poststroke Spasticity, Pain

 

  1. Dressler D, Bhidayasiri R, Bohlega S, Chana P, Chien HF, Chung TM, et al. Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. Journal of Neurology , 2018:265(4):856–62. Available from: https://doi.org/10.1007/s00415-018-8759-1

  2. Bavikatte G, Subramanian G, Ashford S, Allison R, Hicklin D. Early identification, intervention and management of post-stroke spasticity: Expert consensus recommendations. Journal of Central Nervous System Disease , 2021;13:117957352110365. https://doi.org/10.1177/11795735211036576

  3. Kuo C-L, Hu G-C. Post-stroke spasticity: A review of epidemiology, pathophysiology, and treatments. International Journal of Gerontology , 2018;12(4):280–4. Available from: https://doi.org/10.1016/j.ijge.2018.05.005

  4. Rosales R, Balcaitiene J, Berard H, Maisonobe P, Goh K, Kumthornthip W, et al. Early abobotulinumtoxina (Dysport®) in post-stroke adult upper limb spasticity: ONTIME pilot study. Toxins , 2018;10(7):253. Available from: https://doi.org/10.3390/toxins10070253

  5. Dressler D, Altavista MC, Altenmueller E, Bhidayasiri R, Bohlega S, Chana P, et al. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. Journal of Neural Transmission , 2021;128(3):321–35. Available from: https://doi.org/10.1007/s00702-021-02312-4

  6. Jacinto J, Varriale P, Pain E, Lysandropoulos A, Esquenazi A. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in spasticity. Front Neurol [Internet]. 2020;11. Available from: http://dx.doi.org/10.3389/fneur.2020.00388 

  7. Woo J, Mas MF, Zhang J, Wong BS, Stampas A, Francisco GE, et al. Real-world analysis of botulinum toxin (BoNT) injections in post-stroke spasticity: Higher doses of BoNT and longer intervals in the early-start group. Journal of the Neurological Sciences , 2021;425:117449. Available from: https://doi.org/10.1016/j.jns.2021.117449

  8. Rosales RL, Kaňovský P, Fernandez HH. What’s the “catch” in upper-limb post-stroke spasticity: Expanding the role of botulinum toxin applications. Parkinsonism & Related Disorders , 2011;17:S3–S10. Available from: https://doi.org/10.1016/j.parkreldis.2011.06.019

  9. Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology , 2013;80(Issue 3, Supplement 2):S13–S19. Available from: https://doi.org/10.1212/wnl.0b013e3182762448

  10. Harrison RA, Field TS. Post stroke pain: identification, assessment, and therapy. Cerebrovascular Diseases , 2015;39(3-4):190–201. Available from: https://doi.org/10.1159/000375397

  11. Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early development of spasticity following stroke: a prospective, observational trial. Journal of Neurology , 2010:257(7):1067–72. Available from: https://doi.org/10.1007/s00415-010-5463-1

  12. Shaikh A, Phadke CP, Ismail F, Boulias C. Relationship between botulinum toxin, spasticity, and pain: a survey of patient perception. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques , 2016;43(2):311–15. Available from: https://doi.org/10.1017/cjn.2015.321

  13. Sunnerhagen KS, Olver J, Francisco GE. Assessing and treating functional impairment in poststroke spasticity. Neurology , 2013;80(3 Suppl 2):S35–S44. Available from: https://doi.org/10.1212/WNL.0b013e3182764aa2

  14. Francisco G, Balbert A, Bavikatte G, Bensmail D, Carda S, Deltombe T, et al. A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus. Journal of Rehabilitation Medicine , 2021;53(1):jrm00134. Available from: https://doi.org/10.2340/16501977-2753.

  15. Rosales RL. Dystonia, spasticity and Botulinum toxin therapy: Rationale, evidences and clinical context. R.L. Rosales (Ed.). Dystonia: The Many Facets . 2012 Croatia: InTech.

  16. Siongco PRL, Rosales MCE, Rosales RL. Botulinum toxin injection for pain in muscle spasm and visceromotor disorders: A meta-analytic study. Journal of Medicine, University of Santo Tomas, 2017;1(1), 69–78. Available from: https://doi.org/10.35460/2546-1621.2017-0054

  17. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. Journal of Neural Transmission (Vienna, Austria: 1996) , 2008;115 (4):617–23. Available from: https://doi.org/10.1007/s00702-007-0869-3

  18. Gozum MAL, Rosales RL. Botulinum toxin A therapy in early post-stroke spasticity: Providing a wider treatment avenue. International Journal of Neurorehabilitation , 2016;3(3). Available from: https://doi.org/10.4172/2376-0281.1000207

  19. Intiso D, Basciani M, Santamato A, Intiso M, Di Rienzo F. Botulinum toxin Type A for the treatment of neuropathic pain in neuro-rehabilitation. Toxins , 2015;7(7):2454–80. Available from: https://doi.org/10.3390/toxins7072454

  20. Siongco PRL, Rosales RL, Moore AP, Freynhagen R, Arimura K, Kanovsky P, et al. Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study. Journal of Neural Transmission (Vienna, Austria: 1996), 2020;127(6):935–51. Available from: https://doi.org/10.1007/s00702-020-02163-5

  21. Francisco GE, Jost WH, Bavikatte G, Bandari DS, Tang SFT, Munin MC, et al. Individualized onabotulinumtoxina treatment for upper limb spasticity resulted in high clinician- and patient-reported satisfaction: Long-term observational results from the ASPIRE study. PM & R: the journal of injury, function, and rehabilitation , 2020;12(11):1120–33. Available from: https://doi.org/10.1002/pmrj.12328

  22. Lejeune T, Khatkova S, Turner-Stokes L, Picaut P, Maisonobe P, Balcaitiene J, et al. AbobotulinumtoxinA injections in shoulder muscles to improve adult upper limb spasticity: Results from a phase 4 real-world study and a phase 3 open-label trial. Journal of Rehabilitation Medicine , 2020;52(6):jrm00068. Available from: https://doi.org/10.2340/16501977-2695

  23. Rawicki B, Sheean G, Fung VS, Goldsmith S, Morgan C, Novak I. Cerebral Palsy Institute. Botulinum toxin assessment, intervention and aftercare for paediatric and adult niche indications including pain: International consensus statement. European Journal of Neurology , 2020;17(Suppl 2):122–34. Available from: https://doi.org/10.1111/j.1468-1331.2010.03132.x

  24. Fheodoroff K, Jacinto J, Geurts A, Molteni F, Franco JH, Santiago T, et al. How can we improve current practice in spastic paresis? Eur Neurol Rev [Internet]. 2016;11(2):79. Available from: http://dx.doi.org/10.17925/enr.2016.11.02.79 

  25. Nasb M, Shah SZA, Chen H, Youssef AS, Li Z, Dayoub L, et al. Constraint-induced movement therapy combined with botulinum toxin for post-stroke spasticity: A systematic review and meta-analysis. Cureus , 2021;13(9):e17645. Available from: https://doi.org/10.7759/cureus.17645

  26. Mihai EE, Popescu MN, Iliescu AN, Berteanu M. A systematic review on extracorporeal shock wave therapy and botulinum toxin for spasticity treatment: a comparison on efficacy. Eur J Phys Rehabil Med [Internet]. 2022;58(4). Available from: http://dx.doi.org/10.23736/s1973-9087.22.07136-2 

  27. Wissel J, Fheodoroff K, Hoonhorst M, Müngersdorf M, Gallien P, Meier N, et al. Effectiveness of AbobotulinumtoxinA in post-stroke upper limb spasticity in relation to timing of treatment. Frontiers in Neurology , 2020;11:104. Available from: https://doi.org/10.3389/fneur.2020.00104

  28. Rosales RL, Efendy F, Teleg ES, Delos Santos MM, Rosales MC, Ostrea M, et al. Botulinum toxin as early intervention for spasticity after stroke or non-progressive brain lesion: A meta-analysis. Journal of the Neurological Sciences , 2016;371:6–14. Available from: https://doi.org/10.1016/j.jns.2016.10.005

  29. Rosales RL, Dressler D. Introductory chapter: Botulinum toxin Type A therapy in dystonia and spasticity - What are current practical applications? In: RL Rosales (Ed.) Botulinum Toxin Therapy Manual for Dystonia and Spasticity . London: IntechOpen 2016.

Articles related to the one you are viewing

There are currently no results to show, please try again later

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.